Posted by Michael Wonder on 16 Jul 2021
NICE’s decision not to approve Zytiga ‘frustrating’, says ICR
16 July 2021 - NICE has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the drug in 2020.
In June 2020, NICE initially rejected Zytiga (abiraterone acetate) as a first-line treatment for newly diagnosed, advanced prostate cancer.
Following this initial rejection, NICE announced that it would reconsider its decision. However, the cost-effectiveness watchdog has now concluded that it will not recommend Zytiga.
